U.S. FDA Accepts for Priority Review Supplemental New Drug Application for Oxbryta® (voxelotor) for the Treatment of Sickle Cell Disease in Children Ages 4 to 11

David Linetsky
Point-of-Care Marketing

Amy Giles
Increasing Engagement

Bud Bilanich
Success Coach

Liz Kane
Impactful Strategy

Suma Ramadas, PhD
Medical Affairs

Stacey Gandler
Brand Nourishment

Frank Burrell
Scientific Storytelling

Matthew Durham
Omnidynamic Marketing

Pat Purcell
Meeting Engagement

Brenda Snow
Authentic Patient Voice

Paul Theisen
Patient Acquisition

Matt Turner
Patient Affordability

Joey Cohen
Medication Adherence

Daniel Sontupe
Market Access